Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP

14 Apr 20264 min read0 viewsJournal Feed

GIST

Journal of Clinical Oncology, Ahead of Print.

Clinical Editorial

Summary

Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 14 Apr 2026. The item focuses on Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP. Open the detail page to review the full original feed content.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

ClinicalTrialsRelated by Drugpembrolizumab

Surgical Pembro +/- Olaparib w TMZ for rGBM

Oncology • 04 Mar 2026

Nat Rev OncRelated by Drugpembrolizumab

Did ATOMIC Really Improve on the Standard of Care for Mismatch Repair-Deficient Colon Cancer?

Oncology • 23 Apr 2026

Nat Rev OncRelated by Drugpembrolizumab

Did ATOMIC really improve on the standard of care for mismatch repair-deficient colon cancer?

Oncology • 23 Apr 2026

Br J CancerRelated by Drugpembrolizumab

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation

Oncology • 18 Apr 2026

Br J CancerRelated by Drugpembrolizumab

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation

Oncology • 18 Apr 2026

ESMO OpenRelated by Drugpembrolizumab

Durvalumab Plus Weekly Carboplatin and Paclitaxel in Cisplatin-Ineligible Recurrent or Metastati

Oncology • 09 Apr 2026

Feed Metadata

Source

Journal of Clinical Oncology (JCO)

Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP

GIST

Clinical Editorial

Summary

Source Reference

Related by Condition/Drug

Surgical Pembro +/- Olaparib w TMZ for rGBM

Did ATOMIC Really Improve on the Standard of Care for Mismatch Repair-Deficient Colon Cancer?

Did ATOMIC really improve on the standard of care for mismatch&#xa0;repair-deficient colon cancer?

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation

Durvalumab Plus Weekly Carboplatin and Paclitaxel in Cisplatin-Ineligible Recurrent or Metastati

Did ATOMIC really improve on the standard of care for mismatch repair-deficient colon cancer?